Dow Pharmaceutical Sciences   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Petaluma CA United States (1897)
Status: Acquired by Bausch Health Companies (2008)

Organization Overview

First Clinical Trial
2006
NCT00663286
First Marketed Drug
1954
bacitracin (polysporin)
First NDA Approval
2014
efinaconazole (jublia)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dow Hickam Pharmaceuticals | DOW PHARM

Active Ingredients

Marketed Drugs (14)

bacitracin (polysporin) (1954)

clindamycin (cleocin) (2008)

efinaconazole (jublia) (2014 NDA)

erythromycin (ilosone) (1985)

gramicidin

isoniazid (nydrazid) (1971)

methoxsalen (1986)

neomycin (1954)

piperacetazine (quide) (1969)

polymyxin b sulfate (poly-rx) (1954)

tazarotene (tazorac) (2019)

tretinoin (Retin-A) (2007)

ulobetasol propionate (Ultravate) (2018)

urea (1972)

Drugs in Phase 3 Trials (6)

Key: Dow Pharmaceutical Sciences (5) Acquired (1)

aciclovir (zovirax) (1 trial)

benzoyl peroxide (clearasil) (2 trials)

clindamycin (cleocin) (2 trials)

efinaconazole (jublia) (3 trials)

tea (1 trial)

ulobetasol propionate (Ultravate) (5 trials)

Drugs in Phase 2 Trials (3)

fosphenytoin (Cerebyx) (1 trial)

idp-107 (2 trials)

idp-115 (1 trial)

Drugs in Phase 1 Trials (1)

Key: Dow Pharmaceutical Sciences (0) Acquired (1)

menadiol (synkavite) (1 trial)

Indications

Approved Indications


 

Onychomycosis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Onychomycosis (Phase 3)

Psoriasis (Phase 3)

Rosacea (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 10